RALEIGH, N.C., Nov 12, 2010 (BUSINESS WIRE) -- BioDelivery Sciences International (Nasdaq: BDSI) has scheduled a conference call for Monday, November 15, 2010 at 11:00 a.m. Eastern Time to address analyst and shareholder questions regarding the Company's recently filed Form 10-Q for the period ending September 30, 2010. In addition, management will be providing progress updates on BDSI's BEMA Buprenorphine Phase 3 clinical program for the treatment of chronic pain, ONSOLIS manufacturing, and the ONSOLIS "REMS" program.
The conference call can be heard live by dialing toll-free (877) 407-9039, or (201) 689-8470. Replay of the call will be made available for two weeks and can be accessed by dialing (877) 870-5176 or (858) 384-5517 and using replay pin number 361097. In addition, interested parties can also access a live webcast of the conference call from BDSI's corporate website at www.bdsi.com. The webcast will be archived for 30 days following the call.
About BioDelivery Sciences International BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care. BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology. ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the EU (where it is marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer. The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.). BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation for the treatment of opioid dependence. Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron) and migraine (BEMA "Triptan"). BDSI's headquarters is located in Raleigh, North Carolina. For more information, visit www.bdsi.com.
BDSI(R) and BEMA(R) are registered trademarks of BioDelivery Sciences International, Inc. ONSOLIS(R) is a registered trademark of Meda Pharmaceuticals, Inc. BREAKYL is registered trademark of Meda Pharma GmbH & Co.
Cautionary Note on Forward-Looking Statements This press release and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
SOURCE: BioDelivery Sciences International, Inc.
CONTACT: BioDelivery Sciences International, Inc. Al Medwar, 919-582-9050 Vice President, Marketing and Corporate Development firstname.lastname@example.org Copyright Business Wire 2010 -0- KEYWORD: United States
North Carolina INDUSTRY KEYWORD: Health
FDA SUBJECT CODE: Advisory